Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00796159 |
This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Olmesartan medoxomil |
Phase IV |
Study Type: | Observational |
Study Design: | Case-Only, Cross-Sectional |
Official Title: | A Post-Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20 Mg In Combination With 12.5 Mg Of Hydrochlorothiazide In Subjects With Mild To Moderate Essential Hypertension |
Estimated Enrollment: | 3000 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Olmesartan medoxomil + HCTZ |
Drug: Olmesartan medoxomil
olmesartan medoxomil 20 mg and HCTZ 12.5 mg
|
Non Probability Sampling
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Filipino patients with Uncontrolled Mild to Moderate Essential Hypertension
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A0021004 |
Study First Received: | November 20, 2008 |
Last Updated: | January 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00796159 History of Changes |
Health Authority: | Philippines: Bureau of Food and Drugs |
Efficacy; Tolerability; Safety; Essential Hypertension |
Angiotensin II Type 1 Receptor Blockers Essential Hypertension Sodium Chloride Symporter Inhibitors Diuretics Vascular Diseases Olmesartan medoxomil |
Cardiovascular Agents Angiotensin II Antihypertensive Agents Hydrochlorothiazide Hypertension |
Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Olmesartan medoxomil Cardiovascular Agents Antihypertensive Agents |
Hydrochlorothiazide Pharmacologic Actions Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Hypertension |